Alkermes/Reliant Merger: Can Lescol Follow Altace Model?
Executive Summary
Alkermes hopes Lescol will follow the model of King's Altace as a late bloomer in the cardiovascular market following the proposed acquisition of Reliant Pharmaceuticals
You may also be interested in...
Lescol sNDA For Post-Angioplasty Adds 1 Mil. Potential Patients Per Year
Reliant will target the 1 mil. U.S. patients who undergo angioplasty procedures each year who could benefit from Lescol (fluvastatin) and Lescol XL after approval of an expanded indication for the statin May 27
Lescol sNDA For Post-Angioplasty Adds 1 Mil. Potential Patients Per Year
Reliant will target the 1 mil. U.S. patients who undergo angioplasty procedures each year who could benefit from Lescol (fluvastatin) and Lescol XL after approval of an expanded indication for the statin May 27
King Acquisition Strategy Will Be Driven By Late-Stage Product Deals
King Pharmaceuticals is shifting its acquisition strategy to either purchasing or in-licensing late-stage drugs rather than already-marketed products, the company told investors during a quarterly conference call May 6